Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

SEHK:6990 Voorraadrapport

Marktkapitalisatie: HK$41.0b

Sichuan Kelun-Biotech Biopharmaceutical Toekomstige groei

Future criteriumcontroles 5/6

Sichuan Kelun-Biotech Biopharmaceutical is forecast to grow earnings and revenue by 7.6% and 24.6% per annum respectively. EPS is expected to grow by 6.4% per annum. Return on equity is forecast to be -1.2% in 3 years.

Belangrijke informatie

7.6%

Groei van de winst

6.4%

Groei van de winst per aandeel

Biotechs winstgroei41.8%
Inkomstengroei24.6%
Toekomstig rendement op eigen vermogen-1.2%
Dekking van analisten

Good

Laatst bijgewerkt22 Oct 2024

Recente toekomstige groei-updates

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 21
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results

Mar 27
Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results

Recent updates

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

Aug 21
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Beat Analyst Profit Forecasts, And Analysts Have New Estimates

We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth

Jun 14
We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth

Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results

Mar 27
Analysts Have Lowered Expectations For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) After Its Latest Results

An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued

Jan 11
An Intrinsic Calculation For Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG:6990) Suggests It's 45% Undervalued

Winst- en omzetgroeiprognoses

SEHK:6990 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (CNY Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/20262,591-163-1225715
12/31/20251,663-622-496-39215
12/31/20241,827-246-473-51815
6/30/20241,877-187-567-480N/A
3/31/20241,709-354-295-210N/A
12/31/20231,540-522-2360N/A
9/30/20231,523-427135207N/A
6/30/20231,505-333292355N/A
3/31/20231,155-440-942N/A
12/31/2022804-548-310-271N/A
12/31/202132-823-581-486N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: 6990 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Winst versus markt: 6990 is forecast to become profitable over the next 3 years, which is considered above average market growth.

Hoge groeiwinsten: 6990 is expected to become profitable in the next 3 years.

Omzet versus markt: 6990's revenue (24.6% per year) is forecast to grow faster than the Hong Kong market (7.7% per year).

Hoge groei-inkomsten: 6990's revenue (24.6% per year) is forecast to grow faster than 20% per year.


Groeiprognoses winst per aandeel


Toekomstig rendement op eigen vermogen

Toekomstige ROE: 6990 is forecast to be unprofitable in 3 years.


Ontdek groeibedrijven